Rituximab for COVID-19 Vaccine-Associated Pemphigus Vulgaris

Am J Ther. 2023 Nov-Dec;30(6):e544-e546. doi: 10.1097/MJT.0000000000001620. Epub 2023 Mar 7.

Authors

Hai-Zhen Hui^{1

2}, Ying-Jun Wang^{1

2}, Jia-Rong Cheng^{1

2}, Han Mao^{1

2}, Hong-Xing Guo³, Qing-Chun Diao¹, Bing-Jun Shi¹

Affiliations

¹ Department of Dermatology, Chongqing Hospital of Traditional Chinese Medicine (Chongqing Clinical Research Center for Dermatology; Chongqing Key Laboratory of Integrative Dermatology Research), Chongqing, P.R. China.
² Guizhou University of Traditional Chinese Medicine, Guiyang, P.R. China; and.
³ Kweichow Moutai Hospital, Renhuai, P.R. China.

PMID: 36881440
DOI: 10.1097/MJT.0000000000001620

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal
COVID-19 Vaccines* / adverse effects
COVID-19* / prevention & control
Humans
Immunologic Factors / adverse effects
Pemphigus* / drug therapy
Rituximab / adverse effects

Substances

Antibodies, Monoclonal
COVID-19 Vaccines
Immunologic Factors
Rituximab